

Histological Evaluation of the Effect of *Tamra Bhasma* (Copper Based Metallic) and *Jasada Bhasma* (Zinc Based Mineral) Formulations on Testis of Wistar Albino Rats

RAVI BHASKAR¹, MEGHA A DOSHI², S ANJANA³, SHAKUNTHALA R PAI⁴, B RAVISHANKAR⁵,
NAVEEN KUMAR⁶, RAVI MUNDUGARU⁷, SAVITHA HEMALATHA⁸

ABSTRACT

Introduction: The metallic or herbo-mineral preparations used in the Indian system of medicine may cause a toxic effect on mammalian tissues. The broad therapeutic usage of these formulations in the form of *Bhasmas* is required to be ascertained for any adverse effects on the reproductive system.

Aim: Present study was undertaken to evaluate the toxic effects of *Tamra Bhasma* and *Jasada Bhasma* on male gonads using Wistar albino rats.

Materials and Methods: The experimental animals were divided into five different groups comprising of five male rats in each group. Group-I rats were used as the control. Group-II rats received *Tamra Bhasma* at a Therapeutic Dose (TED). Group-III rats received *Tamra Bhasma* at five times of therapeutic dose (TED×5). Group-IV rats received *Jasada Bhasma* at a therapeutic

dose (TED), and Group-V rats received *Jasada Bhasma* five times of therapeutic dose (TED×5) for 28 days. The testes were harvested from these rats, the gross weight of each testes was noted and further processed for histological studies.

Results: Testes of the experimental rats treated with both *Bhasmas* at therapeutic dose level did not show toxicity changes histologically. However, upon the exposure to a higher therapeutic (TED×5) level, it did show the histological features with the indication of decreased spermatogenesis.

Conclusion: Test drugs were relatively safer and did not produce any marked toxic effect. However, at higher doses both drugs may produce toxicity on the testis. The higher dose used in the present study was much higher than routinely practiced clinical doses. Therefore, dose-dependent usage of these *Bhasmas* is recommended.

Keywords: Male gonad, Spermatogenesis, Testes, Toxicity

INTRODUCTION

Metallic and mineral preparation in the form of Ash or *Bhasma* is popular among Ayurvedic physician, which are being used successfully for thousands of years. These formulations had longer shelf-life and efficacy in smaller doses and known to have a broader therapeutic usage [1]. *Bhasma* means ash, which is an inorganic preparation produced by metal or minerals which are eventually converted to the compounds such as carbonates and oxides. *Bhasmas* have gained popularity for their stability, availability, and safety [2,3]. Modern medicine recognises the significant role of metallic and mineral formulations of the alternative medicine in the treatment of several diseases [4].

Tamra Bhasma and *Jasada Bhasma* are the two major products known to be safer in their therapeutic efficacy. *Tamra Bhasma* is ash product of the copper incorporated metallic formulation. This has medicinal values and widely being used in Indian system of alternative medicine. Its usage in the treatment of anaemia, skin disorders, peptic ulcer and lipid metabolic disorders are known to show useful therapeutic qualities [5].

The mineral-based zinc formulation incorporated in *Jasada Bhasma* (also known as *Yashada Bhasma*) is used to treat several illnesses. *Jasada Bhasma* is known for immune-modulatory medicine, and its zinc supplement is widely used in zinc deficiency slow wound healing and diarrhoea in children. Zinc formulated *Jasada Bhasma*, is considered to be the treatment of choice for diabetes [6]. *Bhasmas*, however, prepared in different media have different compositions thus, may show variable chemical reactions [7].

Our previous studies testing the efficacy of *Tamra Bhasma* and *Jasada Bhasmas* on the vital organs from the gastrointestinal tract

and urinary system revealed no significant pathology. Therefore the safety use of these *Bhasmas* both at their TED and relatively safer at its TED×5 levels on these organs been concluded [5,8].

The *Tamra* and *Jasada Bhasma* are being more popularly used in the traditional Indian medicine than any other. Since its extensive therapeutic usage, an adverse effect if any on the reproductive system needs to be confirmed for the continued usage. The present study, therefore, was undertaken to compare the histopathological changes in testicular tissues upon the exposure to two different formulations namely metallic *Tamra Bhasma* and mineral *Jasada Bhasma* at their TED and TED×5 dose levels using experimental animals.

MATERIALS AND METHODS

Present experimental work was conducted at Srinivas Institute of Medical Sciences, Mukka, Mangaluru, and SDM Centre for Research in Ayurveda and Allied Sciences Udupi, for three years nine months (September 2012-June 2016). The institutional animal ethical committee approval was taken before the experiment with the reference number SDMCA/IAEC/CPCEA/GI04/2011.

Test Drugs and their Dose Level

The human dose concentration of copper formulated *Tamra Bhasma* is 22 mg/kg/body weight [9], whereas the dosage experimental animal was estimated by body surface area ratio by referring to the standard table of Paget & Barnes [10] and on this basis of conversion factor, animal dose level determined to be 1.98 mg/kg (therapeutic dose) and 9.9 mg/kg body weight (five times of therapeutic dose). Similarly, the human dose concentration of zinc formulated *Jasada*

Bhasma is used for the therapeutic activity is 120 mg/kg/body weight. However, for the experimental purpose animal dose was estimated to be 10.8 mg/kg (therapeutic dose) and 54 mg/kg body weight (five times of therapeutic dose) [4].

Accordingly, working dose of both the test drug was suspended in 0.5% Carboxymethyl Cellulose (CMC) based upon the body weight of animals (1 mL/100 g body weight) was prepared separately and the same was administered orally by using a catheter.

Study Design

Total of 25 Wistar albino male rats weighing 150-225 g body weight were used divided into five different groups randomly. Each group comprised of five rats. All the animals were fed with rat diet and water, add libitum and acclimatised them to the standard laboratory conditions.

Group-I rats were used as the control and received only vehicle (0.5% CMC). Group-II rats received *Tamra Bhasma* at a therapeutic dose (TED) 1.98 mg/kg. Group-III rats received *Tamra Bhasma* at five times of therapeutic dose (TED \times 5), i.e., 9.9 mg/kg body weight. Group-IV rats received *Jasada Bhasma* at a Therapeutic Dose (TED) of 10.8 mg/kg body weight, and Group-V rats received *Jasada Bhasma* five times of Therapeutic Dose (TED \times 5), i.e., 54 mg/kg body weight.

Both the test drugs were administered to the specified groups for 28 consecutive days [11]. On the 28th day, all the animals from each group were sacrificed, and the testes of each animal were dissected out for the gross weight changes among the group animals and histopathological investigations [12,13]. The routine Haematoxylin and Eosin (H&E) stain has been employed on the paraffin sections, and the cytoarchitecture of testicular morphology has been studied under the light microscope.

STATISTICAL ANALYSIS

The data obtained were expressed in mean \pm SEM and statistical analysis of variance (ANOVA) test performed using SPSS version 16.0, for determining the level of significance of the observed effects. The p-value of less than 0.05 was considered to be statistically significant.

RESULTS


The data related to the effect of *Tamra Bhasma* and *Jasada Bhasma* on the gross weight of testes has been depicted in the [Table/Fig-1]. The data showed that there is an apparent increase in testis weight in *Tamra Bhasma* and *Jasada Bhasma* treated groups compared to normal control at both TED and TED \times 5 dose levels. However, the values were statistically significant only at TED \times 5 dose levels (p<0.001).

Group	Testis weight (g) Mean \pm SEM	% Change
I. Control	2.57 \pm 0.15	-
II. <i>Tamra Bhasma</i> at TED	2.72 \pm 0.09	8.81 \uparrow
III. <i>Tamra Bhasma</i> at TED \times 5	2.93 \pm 0.14	14.22 \uparrow^*
IV. <i>Jasada Bhasma</i> at TED	2.73 \pm 0.15	8.61 \uparrow
V. <i>Jasada Bhasma</i> at TED \times 5	2.94 \pm 0.06	14.42 \uparrow^*


[Table/Fig-1]: Effect of *Tamra Bhasma* and *Jasada Bhasma* on testis weight. TED-Therapeutic dose level, TED \times 5-five times of therapeutic dose level, \uparrow increased change. Data expressed in Mean \pm SEM, *The mean difference is significant at 0.001 level in comparison to normal control

The histological sections of the testis of rats treated with *Tamra Bhasma* and *Jasada Bhasma* at the therapeutic dose level (i.e., group II and IV rats) did not show any toxic changes so that they retained their cytoarchitecture as normal as that of normal control (group I) rats [Table/Fig-2a,b,d]. However, slight morphological variation owing to altered spermatogenic features than that of normal features was observed in the testicular tissues of the rats group (III) treated with five times of therapeutic dose of *Tamra Bhasma* [Table/Fig-2c,3a]. But, remarkably decreased spermatogenic architecture

at test drug administered at the therapeutic dose of *Jasada Bhasma* in group V rats were apparent histologically as there are many vacuoles in the various stages of spermatogenesis in more number of seminiferous tubules [Table/Fig-2e,3b].



[Table/Fig-2]: Showing the histopathological features of testis when compared to normal: (a) to that of exposure to *Tamra Bhasma* at therapeutic dose; (b) and at five times of therapeutic dose levels; (c) *Jasada Bhasma* at therapeutic dose; (d) and at five times of therapeutic dose; (e) levels. Asterisks (in c) and thick arrow heads (in e) are showing the degenerative changes in the seminiferous tubules.



[Table/Fig-3]: High magnification figures of testes sections exposed to five times of therapeutic dose of *Tamra Bhasma* (a) and *Jasada Bhasma* (b) with the features of degenerative changes in the form of vacuoles within the stratified epithelium lining of the seminiferous tubules (H&E stain, 100x).

DISCUSSION

Evaluation of safety and efficacy of mineral-based preparations need to be carefully monitored in the field of biomedical sciences. A novel approach in this regard by Bhaskar R et al., reported useful findings in the scientific literature [5,8]. The histomorphology of various vital organs studied at the exposure of both the dose levels (TED and TED \times 5) revealed no remarkable toxicity changes except a mild sinusoidal dilation in the liver with moderate diffused micro fatty changes and necrotic changes in tubular epithelium of the kidneys at higher concentrate dose levels of both *Bhasmas* [5,8]. These minor histopathological changes in the organs were perhaps due to incomplete processing of the formulations of *Bhasmas*. Improper processing of the *Bhasmas* known to contaminate with the metal ion impurities which could result in various adverse effects and toxicity following its therapeutic usage in higher concentration [6].

In the present study, an attempt has been made to evaluate the efficacy and safety use of *Tamra Bhasma* and *Jasada Bhasma* on the male reproductive organ of the Wistar albino rats. Like other organs, the testis of the experimental rats treated with these *Bhasmas* at usual Therapeutic Dose Level (TED) was not showing any toxicity changes in the histological study. However, upon the exposure to a higher concentration level (TED \times 5), the histological features were suggestive of decreased spermatogenesis and moderate oedematous changes. These features were more apparent in *Jasada Bhasma* exposed testis compared to that of *Tamra Bhasma* with the evident of observable morphological alteration in the cyto-architecture. In supportive of this, the significant increase in gross weight of the testes following the exposures to higher concentrations of both *Bhasmas* is a clear indication of its adverse effect.

Sanjay Kumar YR et al., reported safety usage of *Tamra Bhasma* upto dose 13.5 mg/kg body weight for 28 days and 90 days for sub-acute toxicity and chronic toxicity respectively, in Wistar rats [11].

Previous studies have also witnessed the effective and safe use of *Jasada Bhasma* provided it is properly processed and administered. It implies, the different chemical compositions and biological activities of the *bhasma* preparations said to have specific clinical efficacy depending on the media of its preparation [14].

Since the organ weight is a sensitive index in any pathological scenario, increased weight may be suggestive of oedema, hyperplasia or hypertrophy of the tissues. The present study observation confirms safer usage of both *Tamra Bhasma* and *Jasada Bhasma* at its therapeutic dose level, than that of its higher concentration as used in the current experimental study. At five-times therapeutic dosage, the weights of the testes have remarkably increased probably owing to mild oedematous changes that could be an indication for the decreased spermatogenesis.

Thus, the overall histopathological examinations exhibiting some changes in testes sections deserve some attention while administration of *Bhasmas* of higher concentration with testicular functional monitoring would be a prudent step in clinical settings. Though the usage of *Tamra Bhasma* is relatively safer than *Jasada Bhasma*, the metal *Tamra* is attributed with *AshtaMahaDosha* because of the toxic nature due to its improper purification [15]. Therefore, one should be cautious while using *Tamra Bhasma*. Meanwhile, the possible immune-modulatory quality of *Jasada Bhasma* to have protective role against systemic level damage by lowering the oxidative stress in the organs as quoted by Chandran S et al., is also cannot be ignored [14].

LIMITATION

The prolonged duration of exposure of higher dose level may completely arrest the spermatogenesis. So, extended follow-up should have been carried out which is the limitation of the present study. In future, comprehensive purification in the preparation of *Bhasmas* using analytical and imaging techniques is warranted to determine its particle size, density together with its physical and chemical stability. It is essential to rule out the effect of these test drugs causing changes at the molecular level to correlate with the significant mutagenesis potential. So genotoxicity profile of these formulations could give more relevant results in supportive of our findings.

CONCLUSION

In the present study, we have evaluated a toxicity test on the testes by the usage of two popular *Bhasma* formulations popularly used in Indian system of medicine. From the acute and sub-acute toxicity study, we can conclude that test drugs were relatively safer and did

not produce any marked toxic effects at their therapeutic dose levels. However, at higher doses both drugs may produce toxicity on male gonads, which could have an adverse effect on spermatogenesis. The higher dose used in the present study was much higher than routinely practiced clinical doses. Therefore, dose-dependent usage of these *Bhasmas* is recommended.

SCOPE FOR FURTHER STUDY

It is essential to rule out the effect of these test drugs causing changes at the molecular level to correlate with the significant mutagenesis potential. So, genotoxicity profile of these formulations could give more relevant results in supportive of our findings.

REFERENCES

- [1] Shodhganga.inflibnet.ac.in/bitstream/10603/38973/5/05/chapter1
- [2] Sharma P. *KaiyyadevaNigantu-PathyaVibodhaka*. 1st edition. Varanasi: ChaukhambaOrientalia. 1979. pp 696, 703.
- [3] Joshi N, Sharma K, Peter H, Dash MK. Standardization and quality control parameters for *MuktaBhasma* (calcinedpearl). *Anc Sci Life*. 2015;35(1):42-51.
- [4] Chaudhari SY, Jagtap CY, Galib R, Bedarkar PB, Patgiri B, Prajapati PK. Review of research works done on *Tamra Bhasma* [Incinerated Copper] at Institute for Post-Graduate Teaching and Research in Ayurveda, Jamnagar. *Ayu*. 2013;34(1):21-25.
- [5] Bhaskar R, Doshi MA, Pai SR, Ravishankar B. Evaluation of histopathological and biochemical changes of *Tamra Bhasma* (A copper-based mineral formulation) repeated dose toxicity study in Wistar Albino rats. *Int J Anat Res*. 2016;4(4):3246-52.
- [6] Rinku DU, Kishore MP. *JasadaBhasma*, a zinc-based ayurvedic preparation: contemporary evidence of antidiabetic activity inspires development of a nanomedicine," *Evidence-Based Complementary and Alternative Medicine*. 2015;2015:193156.
- [7] Sadananda S. 'Rasatarangini', Choukamba publications, Ed 2004. pp. 480, 772 (19 chapter-125 sloka).
- [8] Bhaskar R, Megha AD, Anjana S, Shakunthala RP, Naveen K, Ravi S, et al. Pathological and biochemical evaluation of toxic effects of repeated administration of *Jasada Bhasma* (Zinc Ash Formulation) in wistar albino rats. *Journal of Clinical and Diagnostic Research*. 2018;12(7):AC01-AC04.
- [9] Sharma S. *Rasa Tarangini*. Ch. 17, Ver. 40-42. New Delhi: MotilalaBanarsidas Publication; 2009. Pp. 416.
- [10] Paget GE, Barnes JM. Evaluation of drug activities. In: Lawrence DR, Bacharach AL, editors. *Pharmacometrics*. Vol. 1. New York: Academic press; 1964. Pp. 161.
- [11] Sanjay Kumar YR, Sudhesh GN, ThamaizhSelvam N, Acharya MV. Evaluation of Safety of *TamraBhasma* through Sub acute (28 days) and Chronic toxicity (90 days) studies in Wistar rats. *International Journal of Pharma Sciences and Research*. 2016;7(11):431-39.
- [12] Bancroft JD, Gamble M. *Theory and practice of histological techniques*. 5th ed. Queen's Medical Centre, Nottingham, UK; Churchill Livingstone, 2002.
- [13] Ross MH, Reith EJ. In: *Basic Histology; Text & Atlas*, 13th Edition, Jaypee Brothers, New Delhi, 2013.
- [14] Chandran S, Patgiri B, Galib R, Prasanth D. A review through therapeutic attributes of *Yashadabhasma*. *IJPBA*. 2016;7(5):6-11.
- [15] Madhava U. Reprint Edition. Varanasi: Chaukhamba Bharti Academy; 2007. *Ayurveda Prakasha*, 3/116, *Arthavabodhini Sanskrit Commentary*, *Suspashatavabodhini Hindi Commentory* by Vd. Gulraj Sharma Mishra; Pp. 368.

PARTICULARS OF CONTRIBUTORS:

1. PhD Scholar, Department of Anatomy, Krishna Institute of Medical Sciences, Deemed to be University, Karad, Maharashtra, India.
2. Professor and Head, Department of Anatomy, Krishna Institute of Medical Sciences, Deemed to be University, Karad, Maharashtra, India.
3. Tutor, Department of Anatomy, Srinivas Institute of Medical Sciences and RC, Mukka, Mangalore, Karnataka, India.
4. Professor and Head, Department of Anatomy, Kanachur Institute of Medical Sciences, Mangalore, Karnataka, India.
5. Director, Department of Pharmacology and Toxicology, SDM Research Centre for Ayurveda and Allied Sciences, Udipi, Karnataka, India.
6. Assistant Professor, Department of Anatomy, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.
7. Tutor, Department of Pharmacology, Kodagu Institute of Medical Sciences, Kodagu, Karnataka, India.
8. Senior Technologist, Department of Anaesthesia, Jayadeva Institute of Cardiovascular Centre and Research, Bangalore, Karnataka, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Ravi Bhaskar,
#401, Staff Quarters, Srinivas Institute of Medical Sciences and Research Centre,
Mukka, Mangaluru-574146, Karnataka, Mangalore, Karnataka, India.
E-mail: dravibhaskarr@gmail.com

FINANCIAL OR OTHER COMPETING INTERESTS: None.

Date of Submission: **Aug 22, 2018**
Date of Peer Review: **Sep 01, 2018**
Date of Acceptance: **Nov 12, 2018**
Date of Publishing: **Dec 01, 2018**